DNA vaccines encoding full-length or truncated neu induce protective immunity against neu-expressing mammary tumors

Cancer Research

Volumn 58, Issue 9, 1998, Pages 1965-1971

  Chen, Ying ^a   Hu, Dan ^a   Eling, David J ^a   Robbins, Joan ^a   Kipps, Thomas J ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BREAST TUMOR; CANCER IMMUNIZATION; CONTROLLED STUDY; EXPRESSION VECTOR; GENE OVEREXPRESSION; INTRAMUSCULAR DRUG ADMINISTRATION; MOUSE; NONHUMAN; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME;

ADOPTIVE TRANSFER; ANIMALS; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, ERBB-2; IMMUNITY; IMMUNOBLOTTING; INJECTIONS, INTRAMUSCULAR; INTERLEUKIN-2; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; PLASMIDS; RATS; RECEPTOR, ERBB-2; TRANSFECTION; TUMOR CELLS, CULTURED; VACCINES, DNA;

EID: 0032080809     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Padhy, L. C., Shih, C., Cowing, D., Finkelstein, R., and Weinberg, R. A. Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell, 28: 865-871, 1982.
2. r tumour antigen. Nature (Lond.), 312: 513-516, 1984.
3. Schechter, A. L., Hung, M. C., Vaidyanathan, L., Weinberg, R. A., Yang-Feng, T. L., Francke, U., Ullrich, A., and Coussens, L. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science (Washington DC), 229: 976-978, 1985.
4. Alroy, I., and Yarden, Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett., 410: 83-86, 1997.
5. Graus-Porta, D., Beerli, R. R., Daly, J. M., and Hynes, N. E. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J., 16: 1647-1655, 1997.
6. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
7. van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., and Nusse, R. Neu-protein overexpression in breast cancer: association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med., 319: 1239-1245, 1988.
8. Zhou, D., Battifora, H., Yokota, J., Yamamoto, T., and Cline, M. J. Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. Cancer Res., 47: 6123-6125, 1987.
9. Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Groner, B., and Hynes, N. E. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res., 48: 1238-1243, 1988.
10. Ro, J. S., el-Naggar, A., Ro, J. Y., Blick, M., Frye, D., Fraschini, G., Fritsche, H., and Hortobagyi, G. c-erbB-2 amplification in node-negative human breast cancer. Cancer Res., 49: 6941-6944, 1989.
11. Tsuda, H., Hirohashi, S., Shimosato, Y., Hirota, T., Tsugane, S., Yamamoto, H., Miyajima, N., Toyoshima, K., Yamamoto, T., and Yokota, J. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res., 49: 3104-3108, 1989.
12. Slamon, D. J., Godolpnin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., and Ullrich, A. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (Washington DC), 244: 707-712, 1989.
13. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., and Leder, P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell, 54: 105-115, 1988.
14. Bouchard, L., Lamarre, L., Tremblay, P. J., and Jolicoeur, P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell, 57: 931-936, 1989.
15. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., and Muller, W. J. Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA, 89: 10578-10582, 1992.
16. Disis, M. L., and Cheever, M. A. HER-2/neu protein: a target for antigen-specific immunotherapy of human cancer. Adv. Cancer Res., 71: 343-371, 1997.
17. Pardoll, D. M., and Beckerleg, A. M. Exposing the immunology of naked DNA vaccines. Immunity, 3: 165-169, 1995.
18. McDonnell, W. M., and Askari, F. K. DNA vaccines. N. Engl. J. Med., 334: 42-45, 1996.
19. Conry, R. M., LoBuglio, A. F., Loechel, F., Moore, S. E., Sumerel, L. A., Barlow, D. L., and Curiel, D. T. A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumor activity. Gene Ther., 2: 59-65, 1995.
20. Dougall, W. C., Qian, X., Peterson, N. C., Miller, M. J., Samanta, A., and Greene, M. I. The neu-oncogene: signal transduction pathways, transformation mechanisms, and evolving therapies. Oncogene, 9: 2109-2123, 1994.
21. Earp, H. S., Dawson, T. L., Li, X., and Yu, H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res. Treat., 35: 115-132, 1995.
22. Di Fiore, P. P., Segatto, O., Taylor, W. G., Aaronson, S. A., and Pierce, J. H. EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science (Washington DC), 248: 79-83, 1990.
23. Di Fiore, P. P., Pierce, J. H., Kraus, M. H., Segatto, O., King, C. R., and Aaronson, S. A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (Washington DC), 237: 178-182, 1987.
24. Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Di Fiore, P. P., and Kraus, M. H. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene, 10: 1813-1821, 1995.
25. Hynes, N. E., and Stern, D. F. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim. Biophys. Acta, 1198: 165-184, 1994.
26. Watanabe, A., Raz, E., Kohsaka, H., Tighe, H., Baird, S. M., Kipps, T. J., and Carson, D. A. Induction of antibodies to a κ variable region by gene immunization. J. Immunol., 151: 2871-2876, 1993.
27. Raz, E., Watanabe, A., Baird, S. M., Eisenberg, R. A., Parr, T. B., Lotz, M., Kipps, T. J., and Carson, D. A. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc. Natl. Acad. Sci. USA, 90: 4523-4527, 1993.
28. Xiang, Z., and Ertl, H. C. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity, 2: 129-135, 1995.
29. Peeters, J. M., Hazendonk, T. G., Beuvery, E. C., and Tesser, G. I. Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates. J. Immunol. Methods, 120: 133-143, 1989.
30. Bargmann, C. I., Hung, M. C. and Weinberg, R. A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature (Lond.), 319: 226-230, 1986.
31. Cullen, B. R. Expression of a cloned human interleukin-2 cDNA is enhanced by the substitution of a heterologous mRNA leader region. DNA, 7: 645-650, 1988.
32. Chen, C., and Okayama, H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell Biol., 7: 2745-2752, 1987.
33. Wicks, I. P., Howell, M. L., Hancock, T., Kohsaka, H., Olee, T., and Carson, D. A. Bacterial lipopolysaccharide copurifies with plasmid DNA: implications for animal models and human gene therapy. Hum. Gene Ther., 6: 317-323, 1995.
34. Kipps, T. J., Meisenholder, G. W., and Robbins, B. A. New developments in flow cytometric analyses of lymphocyte markers. J. Clin. Lab. Anal., 12: 237-275, 1992.
35. Donnelly, J. J., Ulmer, J. B., and Liu, M. A. DNA vaccines. Life Sci., 60: 163-172, 1997.
36. Hohlfeld, R., and Engel, A. G. The immunobiology of muscle. Immunol. Today, 15: 269-274, 1994.
37. Ulmer, J. B., Deck, R. R., DeWitt, C. M., Donnhly, J. I., and Liu, M. A. Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: antigen presentation by non-muscle cells. Immunology, 89: 59-67, 1996.
38. Corr, M., Lee, D. J., Carson, D. A., and Tighe, H. Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J. Exp. Med., 184: 1555-1560, 1996.
39. Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994.
40. Suto, R., and Srivastava, P. K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science (Washington DC), 269: 1585-1588, 1995.
41. Arnold, D., Faath, S., Rammensee, H., and Schild, H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J. Exp. Med., 182: 885-889, 1995.
42. Nagata, Y., Furagen, R., Hiasa, A., Ikeda, H., Ohta, N., Furukawa, K., Nakamura, H., Kanematsu, T., and Shiku, H. Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J. Immunol., 159: 1336-1343, 1997.
43. Boon, T., Coulie, P. G., and Van den Eynde, B. Tumor antigens recognized by T cells. Immunol. Today, 18: 267-268, 1997.
44. Coulie, P. G. Human tumour antigens recognized by T cells: new perspectives for anticancer vaccines? Mol. Med. Today, 3: 261-268, 1997.
45. Gerrard, T. L., Terz, J. J., and Kaplan, A. M. Cytotoxicity to tumor cells of monocytes from normal individuals and cancer patients. Int. J. Cancer, 26: 585-593, 1980.
46. Ziegler-Heitbrock, H. W., Moller, A., Linke, R. P., Haas, J. G., Rieber, E. P., and Riethmuller, G. Tumor necrosis factor as effector molecule in monocyte mediated cytotoxicity. Cancer Res., 46: 5947-5952, 1986.
47. Gerrard, T. L., Cohen, D. J., and Kaplan, A. M. Human neutrophil-mediated cytotoxicity to tumor cells. J. Natl. Cancer Inst., 66: 483-488, 1981.
48. Wu, Y., and Kipps, T. J. Deoxyribonucleic acid vaccines encoding antigens with rapid proteasome-dependent degradation are highly efficient inducers of cytolytic T lymphocytes. J. Immunol., 159: 6037-6043, 1997.